by CN Bio. | Oct 27, 2020 | Press releases
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
by CN Bio | Aug 5, 2020 | Press releases
Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading cell culture company that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
by CN Bio. | Mar 2, 2020 | Press releases
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by existing investor CN Innovations Headquarters relocated to larger premises in Cambridge Science Park, a leading UK life sciences...
by CN Bio | Nov 11, 2019 | Press releases
Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic steatohepatitis (NASH) therapeutics. CN Bio launched the program at the American Association for the Study of Liver...
by CN Bio | May 1, 2019 | Press releases
Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology scientific equipment. The agreement will see AXT distribute CN Bio’s innovative bioengineering products to medical...
by CN Bio | Feb 28, 2019 | Press releases
London Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of Technology for Organ-on-Chip systems which connect human tissues from up to 10 organs. CN Bio participated with MIT on a...
